Phase I Study of Intermittent Oral Dosing of the Insulin-like Growth Factor-1 and Insulin Receptors Inhibitor OSI-906 in Patients With Advanced Solid Tumors

Clinical Cancer Research

Volumn 21, Issue 4, 2015, Pages 693-700

  Jones, Robin L ⁱ   Kim, Edward S ^b,l   Nava Parada, Pilar ^c   Alam, Salma ^a   Johnson, Faye M ^d   Stephens, Andrew W ^e   Simantov, Ronit ^h   Poondru, Srinivasu ^f   Gedrich, Rich ^j   Lippman, Scott M ^g   Kaye, Stan B ^a   Carden, Craig P ^k  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b Carolinas Health Care System   (United States)

^c CELGENE CORPORATION   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e Piramal Enterprises Limited   (India)

^f ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

^g UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^h Pfizer Ltd   (United States)

ⁱ UNIVERSITY OF WASHINGTON   (United States)

^j Kolltan Pharmaceuticals   (United States)

^k BALLARAT HEALTH SERVICES   (Australia)

^l Department of Solid Tumor Oncology   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

LINSITINIB; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; 3-(8-AMINO-1-(2-PHENYLQUINOLIN-7-YL)IMIDAZO(1,5-A)PYRAZIN-3-YL)-1-METHYLCYCLOBUTANOL; ANTINEOPLASTIC AGENT; IMIDAZOLE DERIVATIVE; PYRAZINE DERIVATIVE;

ADRENAL CORTEX CARCINOMA; ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; COHORT ANALYSIS; COLORECTAL CANCER; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INTERMITTENT THERAPY; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; FATIGUE; FEMALE; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; OVARY CANCER; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QT PROLONGATION; SARCOMA; SOLID TUMOR; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING; ADOLESCENT; CLINICAL TRIAL; DOSE RESPONSE; MIDDLE AGED; NEOPLASMS; ORAL DRUG ADMINISTRATION; YOUNG ADULT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMIDAZOLES; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; PYRAZINES; YOUNG ADULT;

EID: 84923203848     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-0265     Document Type: Article

References (19)

1. Durai R, Yang W, Gupta S, Seifalian AM, Winslet MC. The role of the insulin-like growth factor system in colorectal cancer: review of current knowledge. Int J Colorectal Dis 2005;20:203-20.
2. Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer 2012;12:159-69.
3. Yakar S, Leroith D, Brodt P. The role of the growth hormone/insulin-like growth factor axis in tumor growth and progression: lessons from animal models. Cytokine Growth Factor Rev 2005;16:407-20.
4. Resnicoff M, Tjuvajev J, Rotman HL, Abraham D, Curtis M, Aiken R, et al. Regression of C6 rat brain tumors by cells expressing an antisense insulinlike growth factor I receptor RNA. J Exp Ther Oncol 1996;1:385-9.
5. Atzori F, Tabernero J, Cervantes A, Prudkin L, Andreu J, Rodríguez-Braun E, et al. A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors. Clin Cancer Res 2011;17:6304-12.
6. Haluska P, Shaw HM, Batzel GN, Yin D, Molina JR, Molife LR, et al. Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751, 871 in patients with refractory solid tumors. Clin Cancer Res 2007;13:5834-40.
7. Kurzrock R, Patnaik A, Aisner J, Warren T, Leong S, Benjamin R, et al. A phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor antagonist, in patients with advanced solid tumors. Clin Cancer Res 2010;16:2458-65.
8. Malempati S, Weigel B, Ingle AM, Ahern CH, Carroll JM, Roberts CT, et al. Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology Group. J Clin Oncol 2012;30: 256-62.
9. Tolcher AW, Sarantopoulos J, Patnaik A, Papadopoulos K, Lin CC, Rodon J, et al. Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J Clin Oncol 2009;27:5800-7.
10. García-Echeverria C, Pearson MA, Marti A, Meyer T, Mestan J, Zimmermann J, et al. In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell 2004;5:231-9.
11. Belfiore A, Frasca F, Pandini G, Sciacca L, Vigneri R. Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr Rev 2009;30:586-623.
12. Garofalo C, Manara MC, Nicoletti G, Marino MT, Lollini PL, Astolfi A, et al. Efficacy of and resistance to anti-IGF-1R therapies in Ewing's sarcoma is dependent on insulin receptor signaling. Oncogene 2011;30: 2730-40.
13. Ulanet DB, Ludwig DL, Kahn CR, Hanahan D. Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy. Proc Natl Acad Sci U S A 2010;107:10791-8.
14. Mulvihill MJ, Cooke A, Rosenfeld-Franklin M, Buck E, Foreman K, Landfair D, et al. Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor. Future Med Chem 2009;1:1153-71.
15. Puzanov I, Lindsay R, Goff L, Sosman J, Gilbert J, Berlin J, et al. A phase I study of continuous oral dosing of OSI-906, a dual inhibitor of insulin-like growth factor-1 and insulin receptors, in patients with advanced solid tumors. Clin Cancer Res 2015;21:701-11.
16. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008;8:915-28.
17. Huang GS, Brouwer-Visser J, Ramirez MJ, Kim CH, Hebert TM, Lin J, et al. Insulin-like growth factor 2 expression modulates Taxol resistance and is a candidate biomarker for reduced disease-free survival in ovarian cancer. Clin Cancer Res 2010 Jun 1;16:2999-3010.
18. Clinical Trials.gov-Study NCT00889382; 2014. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00889382.
19. Molina-Arcas M, Hancock DC, Sheridan C, Kumar MS, Downwarsd J. Coordinate direct input of both KRAS and IGF1 receptor to activation of PI3 kinase in KRAS-mutant lung cancer. Cancer Discov 2013;3:548-63.